Marc Rodger profile picture

Contact Information

Marc Rodger
613 737 8899 ext 74641

ORCID logo


Selected Publications

Rodger MA, Le Gal G, Anderson DR, et al and for the REVERSE II Study Investigators*
Validating the HERDOO2 Rule to Guide Treatment Duration for Women with Unprovoked Venous Thrombosis: A Multi-National Prospective Cohort Management Study
BMJ 2017;365:j1065

Rodger MA, Gris J-C, de Vries JI. Low-molecular-weight heparin does not prevent recurrent placenta-mediated pregnancy complications: an individual patient data meta-analysis of randomized controlled trials Lancet 2016 Nov 26;388(10060):2629-2641

Rodger MA, Hague WM, Kingdom J, et al for the TIPPS Investigators
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial Lancet 2014 Nov 8;384(9955):1673-83.

Rodger MA, Walker MC, Smith GN et al. Is thrombophilia associated with placenta-mediated pregnancy complications. A Prospective Cohort Study. J Thromb Haemost 2014;12:469-478.

Rodger MA, Kahn SR, Wells PS et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179:417-426.